Alumis
Milly Kitty Toor is senior director, commercial development, at Alumis. Milly joined Alumis from Bristol Myers Squibb / Myokardia, where she served as director, HCP marketing leading brand strategy and market development for mavacamten’s launch. Prior to joining MyoKardia, Milly held roles of increasing responsibility at Gilead and ZS Associates for over 10 years with focus on go to market and portfolio strategy. Milly has global healthcare experience as she worked extensively in Europe and did her MBA at HHL (Leipzig Graduate School of Management).
This person is not in any offices
Alumis
Alumis is a precision medicines company looking to eliminate the “all comer” approach that is seen with today’s treatments for people with autoimmune disease. They are leveraging a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug development and immunology, in order to create medicines that change the lives of people with autoimmune disease.